Exton-based biopharmaceutical company Immunome has completed a reverse merger with a Seattle-based company dedicated to making strides in cancer therapies, writes John George for the Philadelphia Business Journal.  

After the deal between Immunome and MorphImmune closed on Sept. 23, a group of investors contributed $125 million to the combined companies. The money will be used for developing company platforms and drug candidate pipelines.  

Within the next 18 months, the company said it expects to submit three new investigational drug candidates, or experimental drugs aimed to target immediate life-threatening conditions.  

The newly merged company will be under the auspices of Immunome and will move its headquarters to Seattle while still maintaining a research lab in Exton. 

Founded in 2006, Immunome uses Memory B cells to build antibody therapeutics. Currently, it’s using its technology to potentially develop a therapy for COVID-19.  

MorphImmune, the company being acquired, specifically focuses on oncology therapeutics.  

Read more about this merger and the forward-thinking innovations the company hopes to achieve in the Philadelphia Business Journal.

What is monoclonal antibody therapy?